Genomics company Illumina (NASDAQ: ILMN) reported Q1 CY2025 results beating Wall Street’s revenue expectations, but sales fell by 1.4% year on year to $1.04 billion. Its non-GAAP profit of $0.97 per share was 3.2% above analysts’ consensus estimates.
Is now the time to buy ILMN? Find out in our full research report (it’s free).
Illumina (ILMN) Q1 CY2025 Highlights:
- Revenue: $1.04 billion vs analyst estimates of $1.04 billion (1.4% year-on-year decline, 0.5% beat)
- Adjusted EPS: $0.97 vs analyst estimates of $0.94 (3.2% beat)
- Adjusted EBITDA: $272.6 million vs analyst estimates of $258.3 million (26.2% margin, 5.5% beat)
- Management lowered its full-year Adjusted EPS guidance to $4.25 at the midpoint, a 7.1% decrease
- Operating Margin: 15.8%, up from 11% in the same quarter last year
- Organic Revenue fell 1.2% year on year, in line with the same quarter last year
- Market Capitalization: $13.45 billion
StockStory’s Take
Illumina’s first quarter results reflected the resilience of its clinical sequencing business and ongoing adoption of its NovaSeq X platform. Management highlighted continued momentum in clinical instrument placements, with CEO Jacob Thaysen noting, “NovaSeq X instruments continue to perform well, exceeding our expectations with another quarter of over 60 placements in Q1.” While research and academic customers showed more conservative purchasing behavior due to U.S. funding uncertainty, Thaysen attributed the company’s performance to operational execution and a stable base of high-throughput consumable usage. CFO Ankur Dhingra added that early year ordering activity—particularly long-range purchase commitments—was stronger than in prior years, providing a measure of stability despite broader macroeconomic challenges. Illumina’s ability to maintain operational execution and product adoption under challenging market conditions was a key theme throughout the call.
Looking forward, management’s outlook for the year is shaped by several headwinds, including new export restrictions to China, a constrained research funding environment, and incremental tariffs on imported products. Thaysen acknowledged that these factors have led to a downward revision of full-year earnings guidance, stating, “We are revising our guidance to reflect both the headwinds and the proactive steps we are taking to protect earnings.” The team emphasized ongoing cost reductions, supply chain optimization, and targeted pricing actions as central to mitigating these pressures. Dhingra explained that the company expects to offset about half of the tariff impact in 2025 and sees stronger growth opportunities in clinical markets and new product launches as key to future performance. Management remains focused on advancing its innovation pipeline, particularly in multi-omics, while closely monitoring evolving regulatory and funding developments.
Key Insights from Management’s Remarks
Management attributed the quarter’s results to continued clinical market strength, the successful transition to NovaSeq X, and proactive cost controls, while addressing challenges in China and U.S. research funding.
- Clinical placements drive growth: Illumina’s clinical segment continued to show robust demand, with more than 60 NovaSeq X instruments placed in Q1. This transition is progressing especially well among clinical customers, which management sees as a key lever for volume-driven revenue growth as clinical sequencing expands.
- Research funding pressures: The company noted that research and academic customers became more conservative with consumables purchases in Q1, driven by uncertainty around U.S. government research funding. This softness was most pronounced in the mid-throughput segment, which is more sensitive to delayed instrument purchases and lower utilization.
- China export restrictions: Recent export controls have limited Illumina’s ability to ship sequencing instruments to China, resulting in a significant reduction in projected revenue from the region. Management will now provide separate guidance for Greater China to clarify the underlying performance of the rest of the business.
- Tariff impact and mitigation: New U.S. import tariffs on goods from Singapore and certain other countries are expected to increase Illumina’s costs. The company is actively working to offset these through supply chain changes and selective price increases, though only partial mitigation is anticipated in 2025.
- Cost reduction initiatives: Illumina implemented a $100 million global cost reduction program in March, which is expected to result in flat or slightly down operating expenses for the rest of the year. Management believes these measures, combined with operational discipline, will help protect margins amid ongoing revenue headwinds.
Drivers of Future Performance
Looking ahead, Illumina’s guidance is shaped by geopolitical headwinds, funding constraints, and ongoing cost management, with clinical market expansion and innovation serving as primary growth drivers.
- Clinical market momentum: Management expects continued strength in clinical sequencing to partially offset declines in research-driven revenue. Expanded adoption of newer platforms like NovaSeq X within clinical settings is anticipated to drive higher consumable usage and more predictable revenue streams.
- Tariff and supply chain adjustments: The company is implementing supply chain optimizations and targeted pricing actions to address increased costs from tariffs. Management stated that about half of the tariff impact will be mitigated in 2025, with further actions expected to improve the cost structure in 2026.
- Ongoing innovation pipeline: Illumina highlighted upcoming product launches—including a new single-cell CRISPR research tool and early access proteomics solution—as key to supporting long-term growth. These innovations are designed to expand the multi-omics ecosystem and open new market opportunities, despite near-term market uncertainties.
Catalysts in Upcoming Quarters
In the quarters ahead, our analysts will watch (1) the pace of NovaSeq X adoption and its effect on clinical consumable volumes, (2) the company’s ability to mitigate tariff-related cost increases through supply chain and pricing actions, and (3) the impact of ongoing cost reduction initiatives on operating margins. Key product launches and developments in the regulatory environment for China and research funding will also be important signposts.
Illumina currently trades at a forward P/E ratio of 18.4×. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).
Now Could Be The Perfect Time To Invest In These Stocks
The market surged in 2024 and reached record highs after Donald Trump’s presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025.
While the crowd speculates what might happen next, we’re homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver’s seat and build a durable portfolio by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
